| Peter Stoops D.o. Inc | |
|
13312 Ranchero Rd Ste 16 Oak Hills CA 92344-4802 | |
| (760) 948-0132 | |
| (760) 357-0357 |
| Full Name | Peter Stoops D.o. Inc |
|---|---|
| Speciality | Clinic/Center |
| Location | 13312 Ranchero Rd Ste 16, Oak Hills, California |
| Authorized Official Name and Position | Peter Stoops (CEO) |
| Authorized Official Contact | 7609480132 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Peter Stoops D.o. Inc 13312 Ranchero Rd Ste 16 Oak Hills CA 92344-4802 Ph: (760) 948-0132 | Peter Stoops D.o. Inc 13312 Ranchero Rd Ste 16 Oak Hills CA 92344-4802 Ph: (760) 948-0132 |
| NPI Number | 1851867758 |
|---|---|
| Provider Enumeration Date | 10/17/2018 |
| Last Update Date | 10/17/2018 |
| Medicare PECOS PAC ID | 7315370004 |
|---|---|
| Medicare Enrollment ID | O20191211001067 |
News Archive
Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has established an exclusive licensing agreement with Ramot at Tel Aviv University Ltd., Tel Aviv University's wholly owned technology transfer company.
This week at Analytica 2016, Bruker is showcasing new products and analytical solutions for improved performance and customer experience in pharmaceutical, industrial and applied markets.
CMS has not conducted audits to ensure that Medicare prescription drug plans have implemented programs to prevent fraud as required by law, a lack of oversight that "risks significant misuse of funds in this $39 billion program," according to a Government Accountability Office report scheduled for release on Monday, the AP/Orlando Sentinel reports. For the report, GAO examined five unnamed plans to determine whether they met requirements to participate in the Medicare prescription benefit.
Treatment with an Alpha-1 proteinase inhibitor (A1-PI), a naturally occurring protein that protects lung tissue from breakdown and protects the lung's elasticity, is effective in slowing the progression of emphysema in patients with Alpha-1 antitrypsin deficiency (AATD), a life-threatening genetic disorder, according to a new study presented at the 2013 American Thoracic Society International Conference.
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851867758 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QP2300X | Clinic/center - Primary Care | (* (Not Available)) | Primary |
| 261QU0200X | Clinic/center - Urgent Care | (* (Not Available)) | Secondary |
| Provider Name | Peter J Stoops |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1518912526 PECOS PAC ID: 4688743958 Enrollment ID: I20080513000639 |
News Archive
Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has established an exclusive licensing agreement with Ramot at Tel Aviv University Ltd., Tel Aviv University's wholly owned technology transfer company.
This week at Analytica 2016, Bruker is showcasing new products and analytical solutions for improved performance and customer experience in pharmaceutical, industrial and applied markets.
CMS has not conducted audits to ensure that Medicare prescription drug plans have implemented programs to prevent fraud as required by law, a lack of oversight that "risks significant misuse of funds in this $39 billion program," according to a Government Accountability Office report scheduled for release on Monday, the AP/Orlando Sentinel reports. For the report, GAO examined five unnamed plans to determine whether they met requirements to participate in the Medicare prescription benefit.
Treatment with an Alpha-1 proteinase inhibitor (A1-PI), a naturally occurring protein that protects lung tissue from breakdown and protects the lung's elasticity, is effective in slowing the progression of emphysema in patients with Alpha-1 antitrypsin deficiency (AATD), a life-threatening genetic disorder, according to a new study presented at the 2013 American Thoracic Society International Conference.
› Verified 3 days ago
News Archive
Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has established an exclusive licensing agreement with Ramot at Tel Aviv University Ltd., Tel Aviv University's wholly owned technology transfer company.
This week at Analytica 2016, Bruker is showcasing new products and analytical solutions for improved performance and customer experience in pharmaceutical, industrial and applied markets.
CMS has not conducted audits to ensure that Medicare prescription drug plans have implemented programs to prevent fraud as required by law, a lack of oversight that "risks significant misuse of funds in this $39 billion program," according to a Government Accountability Office report scheduled for release on Monday, the AP/Orlando Sentinel reports. For the report, GAO examined five unnamed plans to determine whether they met requirements to participate in the Medicare prescription benefit.
Treatment with an Alpha-1 proteinase inhibitor (A1-PI), a naturally occurring protein that protects lung tissue from breakdown and protects the lung's elasticity, is effective in slowing the progression of emphysema in patients with Alpha-1 antitrypsin deficiency (AATD), a life-threatening genetic disorder, according to a new study presented at the 2013 American Thoracic Society International Conference.
› Verified 3 days ago